A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Last updated:
2026-09-26
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH DAPAGLIFLOZIN ALONE ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE (BAXDUO-PACIFIC)

Intervention/treatment:
BAXDROSTAT / DAPAGLIFLOZIN
Medical condition:
HYPERTENSION
Protocol code:
D6972C00002
Control number:
290402
Status:
Recruiting
Approved:
October 15, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06742723
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Edmonton, Alberta, T6G 2P4
RECRUITING

British Columbia

Research Site
Surrey, British Columbia, V3T 0H1
RECRUITING
Research Site
Vancouver, British Columbia, V6Z 1Y6
WITHDRAWN

Manitoba

Research Site
Winnipeg, Manitoba, R2V 3M3
RECRUITING

New Brunswick

Research Site
Saint John, New Brunswick, E2L 4L2
RECRUITING

Nova Scotia

Research Site
Halifax, Nova Scotia, B3H 1V7
RECRUITING

Ontario

Research Site
Etobicoke, Ontario, M9W 6V1
RECRUITING
Research Site
London, Ontario, N6A 5A5
RECRUITING
Research Site
Oshawa, Ontario, L1G 2B9
RECRUITING
Research Site
Sarnia, Ontario, N7T 4X3
RECRUITING
Research Site
Toronto, Ontario, M3M 0B2
RECRUITING
Research Site
Toronto, Ontario, M4G 3E8
RECRUITING
Research Site
Toronto, Ontario, M5G 2N2
RECRUITING
Research Site
Toronto, Ontario, M9V 4B4
RECRUITING
Research Site
Waterloo, Ontario, N2T 0C1
RECRUITING

Quebec

Research Site
Laval, Quebec, H7T 2P5
RECRUITING
Research Site
Montreal, Quebec, H1T 2M4
RECRUITING
Research Site
Montreal, Quebec, H2X 0A9
RECRUITING
Research Site
Montreal, Quebec, H4J 1C5
RECRUITING
Research Site
Montreal, Quebec, H4J 1E3
RECRUITING
Research Site
Quebec, Quebec, G1R 2J6
RECRUITING
Did you find what you were looking for?